You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

July 6, 2022

Patent Aspects of Vietnam’s Amended IP Law from a Practitioner’s Perspective

Patent is an essential piece of the amended Law on Intellectual Property (“Amended IP Law”), which was passed by the National Assembly of Vietnam on June 16, 2022, and will take effect on January 1, 2023 (except for the regulation on protection of experimental data for agrochemical products, which will take delayed effect on January 14, 2024).

Among the amended and supplemented contents of the Amended IP Law, there are notable patent-related amendments to Article 60 on assessing the novelty of inventions and Article 96 on grounds for invalidating patent protection titles. We discuss these changes below.

Secret Prior Art Under Article 60.1

A significant amendment to Clause 1, Article 60 of the Amended IP Law on the novelty of inventions is to broaden the scope under which an invention can be considered to have lost its novelty.

For the first time in Vietnam, “secret prior art” –a patent application with an earlier filing date or priority date but published on or after the filing date or priority date of an examined patent application – is introduced as a prior art document.

In the diagram above, at the time of filing of the A2 application, secret prior art A1 has been filed but not yet published, making it inaccessible to the public. At this point, only the A1 applicant and the IP Office are aware of the A1 application.

Under the current provisions of the 2005 IP Law, as amended in 2009 and 2019, the A1 patent application is not eligible to be a prior art document when assessing the novelty of A2. However, based on the “first-to-file principle” and the principle of priority, the IP Office has still had other approaches to bar the patentability of an A2 patent application if there is such an A1 application.

By supplementing the provisions of Article 60.1(b) of the Amended IP Law, the A1 patent application can officially be considered “secret prior art” to assess the novelty of A2. As a result, this amendment provides a more legitimate, direct, and comprehensive tool for assessing novelty using “secret prior art.”

From the provisions of the amended Article 60.1, there are still some ambiguities, such as whether secret prior art is limited to the case where the applicants of A1 and A2 are different (in some countries, secret prior art does not apply if the applicants of A1 and A2 are the same), and whether there is a “domestic limitation,” in which patents filed abroad and not yet published are not considered to be secret prior art in Vietnam. After the Amended IP Law goes into force, the authorities will likely issue more guidance to clarify these ambiguous issues.

Finally, one can see that the provision on the use of “secret prior art” applies only to the assessment of novelty of an invention, not to the degree of inventive step.

New Grounds for Patent Invalidation Under Article 96

Article 96 has been amended to include additional grounds for patent invalidation. The two current grounds are (i) the applicant did not have the right, or did not have the right transferred to him or her, to register the invention, or (ii) the subject matter of the invention did not meet the protection criteria. The Amended IP Law adds the following provisions:

(iii) A patent is invalidated in its entirety if:

  • The patent application is filed in violation of the security control regulations, or
  • The invention is directly created based on genetic resources or traditional knowledge about genetic resources but the patent application does not disclose or incorrectly discloses the origin of the genetic resources or traditional knowledge about genetic resources contained in that application.

(iv) A patent is invalidated in whole or in part if:

  • An amendment expands the scope of the disclosed subject matters or changes the nature of the subject matters claimed in the application;
  • The invention is not sufficiently and clearly disclosed in the specification;
  • The patented invention extends beyond the scope of the disclosure in the original specification; or
  • The invention does not meet the first-to-file principle.

In practice, a number of invalidators have cited these grounds in the past in their patent invalidation requests, but as far as we know, the IP Office has not yet used these factual grounds in any judgment to invalidate a patent. This is the first time that these grounds have been codified in law in Vietnam, which could lead to them being used more often in invalidation requests.

The non-protection of inventions filed in contravention of the provisions on security control is mentioned in the current regulations. However, there are still some unclear and controversial points, such as the identification of “Inventions of Vietnamese organizations and individuals” and “inventions created in Vietnam” as the objects of security control.

The Amended IP Law makes the provisions on security control a basis for invalidating a patent if the patent application is filed in violation of this provision, and it also replaces the above ambiguous terms with a clearer term: “Inventions in technical fields that have an impact on national defense and security, created in Vietnam, and under the registration right of an individual who is a Vietnamese citizen and permanently resides in Vietnam, or of an established organization under Vietnamese law.”

More specific guidelines, however, are still needed to accommodate cases such as inventions partially created in Vietnam; inventions jointly owned by Vietnamese entities and foreign entities; inventions created in Vietnam under the right of registration of Vietnamese entities but transferred to foreign entities before filing, and so on.

The protection of genetic resources and traditional knowledge about genetic resources is provided for in Law on Biodiversity No. 20/2008/QH12, as amended by Law No. 35/2018/QH14. The introduction of regulations on disclosure of genetic resources or traditional knowledge about them in patent applications is in line with the trend of using such resources to create new technical solutions. This provision is intended to add additional measures to avoid the loss of said genetic resources in addition to those provided for in the Law on Biodiversity.

Although not a new concept, the provisions on disclosure of genetic resources or traditional knowledge of genetic resources in patent applications are not mentioned at all in the current IP Law. Therefore, there should be specific guidance on the information to be disclosed in the description, how to assess the disclosed information in the procedure for invalidating a patent based on this ground, etc.

Although mentioned as requirements during the examination of a patent application, the grounds relating to disclosure, amendment of a patent description, or the first-to-file principle have never been recognized as a basis for patent invalidation in the IP Law. It is entirely reasonable to include these grounds for invalidation in the Amended IP Law; however, several parts of the implementation remain unclear, such as the procedure and authority to define a “person of ordinary skills in the respective art.”

Conclusion

In our opinion, the Amended IP Law, which has received a lot of feedback from IP practitioners, is a progressive document that introduces many necessary and reasonable changes for the IP environment in Vietnam. However, there are still some ambiguities that require more clarification and professional advice on how to comprehend and implement these new patent provisions. We believe that the Vietnam IP Office will hold dissemination sessions and discussions on how to apply the Amended IP Law.

RELATED INSIGHTS​ 

September 9, 2026
On August 5, 2026, the Consumer Case Division of Thailand’s Civil Court rendered a judgment in a case involving a beauty clinic that advertised acne scar treatments using claims that the clinic was operated by a specialist physician and that the treatment, allegedly involving stem cell technology, could permanently remove acne scars. The plaintiff brought a claim against both the physician-owner and the clinic company, alleging that the advertisements were false and induced her to purchase the treatment. The court found that the clinic was liable for the false representations and that the physician-owner, as both the authorized director of the company and the medical practitioner who provided treatment, was jointly responsible. Although the plaintiff could not fully prove all damages claimed, the court awarded compensation of THB 20,000, together with interest. While the judgment arose from a consumer protection dispute, it serves as a valuable reminder that medical facility advertisements in Thailand are regulated and may expose clinics and healthcare providers not only to regulatory enforcement but also to civil liability from patients who rely on misleading promotional claims. Regulatory Framework Governing Medical Facility Advertisements Medical facility advertising in Thailand is governed by the Medical Facility Act B.E. 2541 (1998), as amended by the Medical Facility Act (No. 4) B.E. 2559 (2016). The principal secondary legislation is the Department of Health Service Support (DoHSS) Notification Re: Rules, Procedures, Conditions, and Fees for an Advertisement or Publication Concerning a Medical Facility, which came into force on November 25, 2019. Under this notification, “advertising” includes any act, by any means, that causes members of the public to see, hear, or otherwise become aware of a message, sound, or image for the commercial benefit of a medical facility. This broad definition covers not only traditional media but also clinic websites, social
September 9, 2026
On June 30, 2026, Indonesia’s National Agency of Drug and Food Control (BPOM) issued BPOM Regulation No. 11 of 2026 on Food Packaging, which expands the list of approved food-contact substances and recognizes a broader range of permissible functions for those substances. The new regulation, which revokes BPOM Regulation No. 20 of 2019, reflects developments in packaging technology and materials science. Although the new regulation provides more advantages to business actors by adding more food contact substances to the approved list for use in food packaging, there are more stringent rules and restrictions for testing. One of the most significant changes is a comprehensive migration-testing framework that sets out requirements for packaging materials, testing conditions, food simulants, and specific migration limits. Overall and Specific Migration Under BPOM Regulation No. 20 of 2019, migration requirements were primarily set out within the lists of approved food-contact substances and packaging materials. BPOM Regulation No. 11 of 2026 instead expressly requires packaging materials that come into direct contact with food to meet both overall and specific migration limits. These are defined as follows: Overall migration: The total quantity of all substances that migrate from the packaging, regardless of whether the substances are hazardous or nonhazardous to health. Specific migration: The quantity of a particular identified substance known to be hazardous to health that migrates from the packaging. Stricter Limits on Heavy Metals The overall migration limit for plastic packaging remains unchanged under both regulations at 60 mg/kg or 10 mg/dm². However, the new regulation introduces significant changes to the regulation of heavy metals. Under the 2019 regulation, four heavy metals—lead, cadmium, chromium VI, and mercury—were subject to a single combined limit of 1 mg/kg. The 2026 regulation, however, requires each heavy metal to meet its own individual specific migration limit, adds arsenic as
September 7, 2026
Indonesia’s Constitutional Court (Mahkamah Konstitusi) has reinstated a key provision limiting pharmaceutical patent protection, signaling a renewed commitment to balancing patent rights with public access to medicines. In its ruling to Case No. 255/PUU-XXIII/2025, the court partially granted a petition for judicial review of Law No. 65 of 2024, which had amended the country’s Patent Law, and ordered the restoration of a provision that had excluded certain pharmaceutical inventions from patentability. The decision took effect immediately upon its pronouncement at the court’s plenary session on August 28, 2026. Background The petition challenged the removal of article 4(f) from Law No. 13 of 2016 concerning Patents (Patent Law), as amended by Law No. 65 of 2024. Article 4(f) had excluded from patentability certain inventions relating to new uses of known substances. The petitioners argued that removing this provision would open the door to patent protection for second medical use inventions and facilitate patent evergreening—practices that can extend exclusivity periods, delay generic market entry, and reduce public access to affordable medicines. The petitioners included several patient advocacy and public-interest organizations: the Indonesian Dialysis Patients Community Association, the Indonesian Association of Drug Abuse Victims (PKNI), the Indonesian Pulmonary Hypertension Foundation (YHPI), the Rekat Peduli Indonesia Foundation, and the Indonesian Positive Women’s Association (IPPI), along with the Indonesia for Global Justice Association and four individual petitioners. The petitioners also challenged the constitutionality of the phrase “interested party” in article 70(1) of the Patent Law, arguing that it should be construed expressly to clarify who has standing to appeal a decision to grant a patent before the Board of Patent Appeal, and to allow a broader range of parties—such as patent holders, licensees, consumer organizations, prosecutors, aggrieved third parties, and others who may suffer direct or indirect harm from the grant of a patent—to
September 4, 2026
Blind boxes and collectibles have become increasingly popular, driven by the excitement of not knowing which character or design will be revealed until the package is opened. While most visible in the art toy market, the same concept is also used in the food industry. Confectionery, snacks, and other food products are sometimes sold with toys, character figures, cards, or other collectibles. A package might, for example, contain one of ten possible characters, with consumers knowing that an item is included but not which one they will receive. Some collections may also feature rare or “secret” items. For food businesses, however, adding a randomized toy or collectible involves more than a marketing decision. The food, the nonfood item, and the randomized mechanism may each raise different regulatory considerations in Thailand. Thai FDA Requirements for Nonfood Objects Packaged with Food The main food regulatory consideration is Ministry of Public Health Notification No. 310 B.E. 2551 (2008), which regulates food packaged together with things or objects that are not food. Under Notification No. 310, certain nonfood objects may be packaged together with food where they fall within specified exceptions, including objects that serve the following purposes: Maintaining the quality or standard of the food, such as a desiccant or oxygen absorber; Serving as a seasoning or as part of food preparation, such as chili powder sachets or seasoning sachets contained in instant noodle packages; or Functioning as an eating or food-preparation utensil, such as a spoon or fork included with instant noodles. Other nonfood objects that do not fall within these categories generally should not be placed inside the food container together with the food. Where a toy, collectible, or other nonfood object is intended to be sold together with a food product, businesses should therefore carefully consider the nature of